A Phase II/III study with CERC-501 as an adjunctive treatment of major depressive disorder.
Phase of Trial: Phase II/III
Latest Information Update: 05 Dec 2016
At a glance
- Drugs CERC 501 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 05 Dec 2016 According to a Cerecor media release, the company anticipates to initiate this trial in the second half of 2017.
- 24 Sep 2016 New trial record
- 06 Sep 2016 Cerecor is planning to initiate this study in 2017, as reported by a media release.